On March 17th, LakeShore Biopharma Co., Ltd. ("LakeShore bioharma" or "the Company") and Special Purpose Company “Summit Healthcare Acquisition Corp” ("Summit Healthcare" NASDAQ: SMIH) merged its business and was listed on NASDAQ in the United States, with the stock code "LSB"(Formerly "YS").

 According to Beido Finance, LakeShore biopharma had planned to go public on the Hong Kong Stock Exchange. Prior to this, LakeShore biopharma had submitted a prospectus to the Hong Kong Stock Exchange on March 8th, 2021, sprinting to list on the main board of the Hong Kong Stock Exchange, with Morgan Stanley and Haitong International as its joint sponsors. In the end, LakeShore biopharma gave up its plan to list on the Hong Kong Stock Exchange.

In Sep 2022, the company signed a merger agreement with Summit Healthcare, raising up to $230 million through the merger transaction. Among them, Summit Healthcare is a SPAC founded by Fu Wei, founder of CBC Group, with cornerstone investors including Snow Lake Capital, Valliance Capital, and others.

 LakeShore biopharma is a biopharmaceutical company dedicated to discovering, developing, producing, and commercializing a new generation of vaccines and therapeutic biologics, with a focus on infectious diseases and cancer treatment. It is reported that LakeShore biopharma has over 800 employees in China, the United States, Singapore, the United Arab Emirates, and the Philippines.